News Feed

Glenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg

Mumbai, India; October 19, 2020: Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune^®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV.

According to IQVIA^TM sales data for the 12 month period ending August 2020, the Rapamune^® Tablets, 0.5 mg, 1 mg and 2 mg market² achieved annual sales of approximately $119.7 million*.

Glenmark’s current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

—End—

About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com.

For more information:
Glenmark Media Contacts
Udaykumar Murthy
Senior Manager, Corporate Communications
+91 9960377617
corpcomm@glenmarkpharma.com

¹All brand names and trademarks are the property of their respective owners
²Market includes brand and all available therapeutic equivalents
^*IQVIA^TM National Sales Perspectives: Retail & Non-Retail, August 2020

Glenmark Pharmaceuticals receives ANDA approval for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg

Mumbai, India; October 19, 2020: Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune^®1 Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV.

According to IQVIA^TM sales data for the 12 month period ending August 2020, the Rapamune^® Tablets, 0.5 mg, 1 mg and 2 mg market² achieved annual sales of approximately $119.7 million*.

Glenmark’s current portfolio consists of 165 products authorized for distribution in the U.S. marketplace and 45 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

—End—

About Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com.

For more information:
Glenmark Media Contacts
Udaykumar Murthy
Senior Manager, Corporate Communications
+91 9960377617
corpcomm@glenmarkpharma.com

¹All brand names and trademarks are the property of their respective owners
²Market includes brand and all available therapeutic equivalents
^*IQVIA^TM National Sales Perspectives: Retail & Non-Retail, August 2020